Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2010

View Archived Issues

Spiroindolone NITD-609 protective against malaria in rodents

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Palau Pharma identifies new histamine H4 receptor antagonists

Galapagos develops new phosphodiesterase 1A inhibitors for osteoarthritis

Phase III data presented on bisoprolol vs. carvedilol in elderly subjects with CHF

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Researchers discover differential miRNA expression in cervical cancer lesions

Hokkaido University and Shionogi claim new nucleoside-type antibiotics

Aquapharm and Dundee University to codevelop marine compounds for AD

FibroGen receives Chinese approval to begin clinical trials of FG-4592 in CKD anemia

FDA recommends approval of dabigatran etexilate for stroke prevention in AF

New S1P5 receptor agonists and antagonists described by Abbott

Pronova Biopharma and Abbott amend agreement for Omacor

Nippon Shinyaku launches Tramal in Japan for cancer pain

Epitomics and Michael J. Fox Foundation collaborate on LRRK2 antibodies

Clinical testing starts for ImmunoGen's anticancer therapy SAR-566658

CE mark approval for Promus Element stent in patients with diabetes and AMI

Enrollment begins in phase II trial of CYT-107 in chronic HIV infection

Takeda identifies new GPR119 receptor agonists

Pharmalucia claims new agents for bacterial and mycobacterial infections

NeuroSearch reports data from safety extension to phase III Huntexil trial

Data reported from extension study of Qnexa in obesity

Optimer submits rolling NDA for fidaxomicin in C. difficile infection

Tekmira to settle debts with Hana Biosciences

Signum Biosciences receives NIH grants for skin disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...